Form 4: Arthur Butcher Executes Stock Options and Sells Shares
SEC Form 4
Arthur Butcher, EVP at Boston Scientific, exercised stock options and sold 17,313 shares of common stock on August 1, 2025, per a pre-established 10b5-1 trading plan.
Summary
- Arthur C. Butcher, an Executive Vice President at Boston Scientific, executed options to purchase common stock at prices of $27.09, $24.55, $22.71, and $17.26.
- Butcher sold 17,313 shares of Boston Scientific common stock at a weighted average price of $104.6335.
- The transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.
- Following the reported transactions, Butcher directly owns 23,600 shares of common stock and indirectly owns 13,355 shares through a 401(k).
- Butcher holds options to purchase 6,952 shares at $27.09, 1,009 shares at $17.26, 6,175 shares at $24.55 and 3,177 shares at $22.71.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing represents routine execution of stock options and a pre-planned sale of shares.
Positives
- The transactions were executed under a pre-established Rule 10b5-1 trading plan, suggesting a planned and orderly approach to stock transactions.
- Butcher continues to hold a significant number of shares and stock options, indicating continued investment in the company.
Negatives
- Sale of 17,313 shares may be perceived negatively, although it is part of a pre-planned strategy.
Risks
- The filing does not explicitly mention risks.
Future Outlook
There are no explicit forward-looking statements in this filing.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's value and future prospects.
Comparison to Industry Standards
- Comparing the trading activity to peers such as Medtronic (MDT), Abbott Laboratories (ABT), and Stryker (SYK) can provide context. For example, similar filings for executives at these companies can be analyzed to determine if the trading activity is typical for the industry.
- Benchmarking the size of the transaction (17,313 shares) against the executive's total holdings and the company's market capitalization can provide a sense of its significance.
- Analyzing the timing of the transaction relative to earnings releases or other major corporate events can provide additional context.
Stakeholder Impact
- The sale of shares could have a minor impact on shareholders if it signals a lack of confidence by the executive, although the pre-planned nature mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 2017-02-22 | First anniversary of grant of option to purchase shares at $17.26. |
| 2017-06-01 | First anniversary of grant of option to purchase shares at $22.71. |
| 2018-02-28 | First anniversary of grant of option to purchase shares at $24.55. |
| 2019-02-15 | First anniversary of grant of option to purchase shares at $27.09. |
| 2024-08-09 | Date of adoption of Rule 10b5-1 trading plan. |
| 2025-06-30 | Shares acquired under the Company's Employee Stock Purchase Plan. |
| 2025-08-01 | Date of stock option exercise and share sale. |
| 2026-02-22 | Expiration date of stock options granted on February 22, 2017. |
| 2026-06-01 | Expiration date of stock options granted on June 1, 2017. |
| 2027-02-28 | Expiration date of stock options granted on February 28, 2018. |
| 2028-02-15 | Expiration date of stock options granted on February 15, 2019. |
| 2025-08-04 | Date of Form 4 filing. |
Recommendation
holdThe transactions appear to be part of a pre-planned strategy (Rule 10b5-1 trading plan) and do not necessarily indicate a change in the executive's long-term outlook for the company. Therefore, a hold recommendation is appropriate.
Keywords
Form 4, Boston Scientific, BSX, Arthur Butcher, Stock Options, Share Sale, Rule 10b5-1, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.